Intermittent dosing regimen for the treatment of overweight with MTPinhibitors

Details for Australian Patent Application No. 2005230397 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Engelen, Marc Alois Celine Maria; Hoeben, Dagmar Theo Coleta Maria Ghislain

Agent Shelston IP

Pub. Number AU-B-2005230397

PCT Pub. Number WO2005/097131

Priority 04101470.5 09.04.04 EP

Filing date 6 April 2005

Wipo publication date 20 October 2005

Acceptance publication date 8 April 2010

International Classifications

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

Event Publications

12 October 2006 PCT application entered the National Phase

  PCT publication WO2005/097131 Priority application(s): WO2005/097131

8 April 2010 Application Accepted

  Published as AU-B-2005230397

5 August 2010 Standard Patent Sealed

3 November 2011 Assignment Registered

  Janssen Pharmaceutica N.V. The patent has been assigned to Elanco Animal Health Ireland Limited

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230399-Protein kinase C inhibitors for the treatment of autoimmune diseases and of transplant rejection

2005230392-Thiadiazolidinones as GSK-3 inhibitors